growth rates (Fig. 4) . Avastin, which binds vascular endothelial growth factor (VEGF), continues to be market leader in targeted cancer therapies, with US sales of ~$2.6 billion and a growth rate in US sales of 17%. Humirawhich binds to tumor necrosis factor (TNF-α), has US sales of $2.2 billion and a growth rate of 35%-is now the most rapidly growing blockbuster biologic in the US market.
Avastin's growth has been driven by its successful expansion to other high-incidence cancers. In 2009, Avastin was approved for two additional indications, glioblastoma multiforme (GBM) and advanced renal cell carcinoma (RCC). Avastin's other FDA-approved indications include metastatic colorectal cancer (mCRC), metastatic breast cancer (mBC) and non-small cell lung cancer (NSCLC). Growth in the sales of this mAb in 2008 was fueled by its uptake in mBC, where Roche/ Genentech reports its market penetration in first-line HER2-negative mBC has now reached ~40%. Avastin's market penetration has also stabilized in NSCLC, first-line mCRC and second-line mCRC at 65%, 73% and 43%, respectively. During the next 12 months, Avastin's growth is likely to be driven by its use in the two most recently approved (~12%), although this was slower than the growth rate in 2007 of ~22% (Fig. 3) . Total US sales of ~$15.5 billion for mAb products makes this therapeutic class the highest selling class of biologics, although insulins have displaced them from their position as the most rapidly growing class of biologics. With 29 US Food and Drug Administration (FDA)-approved mAbs on the market (and one mAb, Genentech's (S. San Francisco, CA, USA) Raptiva (efalizumab), withdrawn), sales of mAbs constitute ~35% of the total biologics market. The two major indications for mAbs continue to be cancer and inflammatory disorders, garnering ~40% and 38% of total mAb sales in all indications, respectively. Although sales for these indications grew by double-digit rates, revenues generated from mAbs targeting cancer are not growing as fast as they were: their year-over-year (YoY) growth fell to 10% in 2008 compared with a ~20% YoY rate in 2007.
As in previous years, the majority of mAbs sales growth has been fueled by two 'mega' blockbuster mAbs: Roche/Genentech's (Basel) Avastin (bevacizumab) and Abbott's (Deerfield, IL, USA) Humira (adalimumab), each continuing to achieve high double-digit S ince last year's survey of sales of biologics in these pages 1 , the global recession and ongoing safety woes of erythropoietins (EPOs) have continued to slow the growth rate in product revenues from double-digit to single-digit rates. In 2008, total sales of biologics in the United States reached ~$46.5 billion, a 4.5% increase over their 2007 sales (Fig. 1) . Though this growth rate has not kept pace with the growth rates of the past five years, it does compare favorably to the growth of the US pharmaceutical sector, which lagged at only ~1% in 2008 (ref. 2) .
As the overall growth rate of the biotech industry slows, some markets, as well as some biotechs, are experiencing decreasing sales, whereas others have continued to grow at high double-digit rates (12-18%; Figs. 2 and 3). To understand the factors that have slowed the biotech industry and to identify future growth drivers, I analyze here the sales trends in 2008 and the first half of 2009: indication expansions, safety issues and promising new candidates in nine classes of biologics. (I have excluded an analysis of approved nucleic acid products as sales of this group have now dropped below $1 million.) I single out individual drugs within each respective therapeutic class as market leaders, rising stars (rapid growth) or laggards (sales have lagged). The methodology used in this article is essentially the same as in previous biotech market overviews published in this journal 1, 3 . What follows is a summary of sales for each nine categories of biotech drugs presented in order of their size. F E AT U R E jury in Marshall, Texas, ruled in J&J's favor, ordering Abbott to pay $1.7 billion in damages. Abbott has said that it will appeal this decision.
Monoclonal antibodies
In 2008, most other mAbs experienced growth of 10% or more, except for two Roche/ Genentech mAbs, Herceptin (trastuzumab) and Lucentis (ranibizumab), which slowed to low-single digits. The slowdown for Herceptin is primarily due to market saturation, as its penetration in mBC remains high at around ~75%. Lucentis's slowdown could be due to off-label use of Avastin in people with wet agerelated macular degeneration (AMD). An article published in 2006 showed that Avastin was safe and effective for treatment of choroidal neovascularization in AMD patients 4 . Because of these preliminary data and the pricing controversy (Lucentis is a Fab fragment of Avastin that is priced 40 times higher than the original molecule), in 2008 the National Eye Institute of the National Institutes of Health initiated a multicenter clinical trial to compare the relative safety and effectiveness of Lucentis and Avastin in wet AMD treatment. Another threat to Lucentis is Regeneron (Tarrytown, NY, USA) and Bayer's (Leverkusen, Germany) VEGF Trap-Eye, which is currently in late stages of development for wet AMD, and is being tested head-to-head against Lucentis. The future outlook of Lucentis would depend on the outcome of these trials; in the short term, physicians are likely to continue using Avastin off-label for this condition.
The mAb market leader Remicade grew by ~9% in 2008, but lost some market share to Humira. Rituxan (rituximab; Genentech), which had the second largest market share in 2007, grew by 10%, primarily due to increased use for rheumatoid arthritis. Revenue from sales of Synagis (palivizumab; Medimmune, Gaithersberg, MD, USA) increased by 10%, driven mostly by price increases rather than volume.
PA, USA). Similarly in the dermatology market, its prescription share has reached 35%, mainly due to share gains from Amgen's (Thousand Oaks, CA, USA) Enbrel (etanercept). These rapid share gains have fueled Humira's growth rate (~35%), surpassing the TNF-α market growth rate (~10%) by more than threefold.
Last year, a major patent dispute surfaced on the biotech landscape; J&J alleged that Humira infringed the patent for Remicade. In June, a indications, GBM and RCC. Roche/Genentech is currently conducting trials for use of Avastin in combination with chemotherapy in ovarian and prostate cancers, and in combination with aromatase inhibitors in breast cancer.
Humira's high growth is driven by its expanding use in Crohn's and psoriasis markets. In Crohn's, Humira's prescription share has reached ~45%, including significant share gains from Remicade 
Growth factors
The safety woes of the erythropoietins have continued to plague the sales of the growth factors (GF) sector. In 2008, GF sales fell to ~$11 billion, a marked reduction of almost 20% from their peak sales of ~$14 billion in 2006. This decrease was due to label changes FDA enforced for Aranesp (darbepoetin alfa; Amgen) and Procrit (erythropoietin-α; J&J), which restricts their use in patients who are expected to be cured of cancer and patients who have hemoglobin levels greater than 10 g per deciliter of blood. In 2008, the sales of Aranesp and Procrit fell by 31% and 23%, respectively, whereas sales of Epogen (erythropoietin; Amgen) stabilized to its 2007 levels ( Fig. 5 ). Aranesp's and Procrit's sales have declined owing to lower usage in treatment of chemotherapy-induced anemia, whereas Epogen sales have been stable because it is used mainly in individuals with chronic kidney disease. During the first financial quarter of 2009, both Aranesp and Procrit again declined but experienced modest growth in the second quarter, showing some signs of stabilization. Nevertheless, the dark cloud hanging over the EPO market does not seem likely to dissipate any time soon. An imminent danger to their sales lurks in the bundling of payment rates for EPO in people with kidney of the human IL-1 type 1 receptor and the Fc portion of human IgG1.
The outlook for mAbs continues to look bright. Several promising molecules are currently in clinical trials for cancer, Alzheimer's disease, diabetes, lupus and osteoporosis. The most anticipated new mAbs in late-stage human testing include the following: Amgen's denosumab (a fully human mAb that targets receptor activator of nuclear factor κb ligand (RANKL)) for bone metastasis and osteoporosis; J&J and Elan's (Dublin) anti-beta amyloid mAb bapineuzumab for Alzheimer's disease; GlaxoSmithKline (GSK; Brentford, UK) and Genmab's (Copenhagen) fully human anti-CD20 mAb ofatumumab for blood cancers; and Human Genome Sciences (Rockville, MD, USA) and GSK's B-lymphocyte stimulatortargeting human mAb belimumab for systemic lupus erythematosus.
Promising mAb candidates in mid-stage trials include Genentech's two second-generation versions of Herceptin: trastuzumab-DM1 (Herceptin conjugated with ImmunoGen's (Waltham, MA, USA) antimitotic maytansine derivative DM1), and Omnitarg (pertuzumab, a humanized mAb that inhibits dimerization between HER2 and other members of the ErbB family, including epidermal growth factor receptor). Another mAb of note, currently in mid-stage development, is Bristol-Myers Squibb (BMS; New York) and Medarex's (Princeton, NJ, USA) cytotoxic T-lymphocyte antigen 4 (CTLA4) antagonist ipilimumab for melanoma.
It is difficult to make predictions for mAbs earlier in the pipeline. But in terms of mAbs that are in early-stage testing that could have On the safety front, during 2008, the sales of three mAbs were affected by the risk of progressive multifocal leukoencephalopathy (PML) infection. In February 2009, FDA issued a public health advisory about reports of PML in individuals using Raptiva, approved for psoriasis. According to the FDA, three patients had died due to PML. In April 2009, Genentech announced that it was withdrawing Raptiva from the market. The second mAb to face the PML issue was the mega blockbuster Rituxan. In June 2009, a study called RADAR published in the journal Blood 5 , reported that between 1997 and 2008, 57 individuals taking Rituxan developed PML. This report is unlikely to affect Rituxan's use in non-Hodgkin's lymphoma patients because they are known to have a risk of PML. However, this finding could limit Rituxan's sales in rheumatoid arthritis (although currently rheumatoid arthritis constitutes only 10% of Rituxan's sales). From 2008 to date, a total of ten cases of PML were reported in individuals treated with Biogen Idec's Tysabri (natalizumab). The continuing occurrence of PML cases has dampened the long-term growth outlook for Tysabri.
Three new mAbs on the market in 2008 were J&J's Simponi (golimumab) and Stelara (ustekinumab) and Novartis's (Basel) Ilaris (canakinumab). The first two of these molecules are likely to influence the market dynamics of other biologics that target TNF-α.
Simponi is a self-administered injection formulation of anti-TNF-α, with once-monthly dosing, indicated for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Simponi is the next-generation version of Remicade, and joins four other anti-TNF-α molecules (Humira, Enbrel, Remicade and Cimzia (certolizumab), a PEGylated Fab fragment against TNF-α). J&J's other new product, Stelara, is indicated for plaque psoriasis and acts through a novel mechanism by binding the 40-kDa protein subunit of interleukin (IL)-12 and IL-23. Because of its superior efficacy (shown in head-to-head phase 3 trial data), Stelara is likely to steal some share from two anti-TNF-α molecules-Enbrel and Humirawhich are also indicated for plaque psoriasis. Simponi's launch is a sign of future crowding of the biologics market, especially the lucrative anti-TNF-α market. With crowding, it is likely that the price or cost effectiveness of these drugs could become a competing factor.
Ilaris is a mAb against IL-1, indicated for an ultra orphan disease called cryopyrin-associated periodic syndrome (CAPS). It is the second biologic to be indicated for use in CAPS, the first being Regeneron's (Tarrytown, NY, USA) Arcalyst (rilonacept), which is a fusion and second quarters, Levemir sales grew by 16% and 11%, respectively.
Another class of hormones that have been affected by adverse events is glucagon-like peptide-1 (GLP-1) analogs. Currently, only one FDA-approved GLP-1 analog exists, Amylin's (San Diego) twice-daily administered Byetta (exenatide), sales of which dramatically slowed down after it was linked to a dangerous form of pancreatitis. In 2008, Byetta US sales growth slowed to 10%, compared with 47% in 2007. Another safety issue that might have affected Byetta's sales is the elevated risk of thyroid cancer associated with animals exposed to NovoNordisk's (Bagsvaerd, Denmark) GLP-1 analog, Victoza (liraglutide; Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1 ), which is currently in late-stage clinical trials. These risks of serious diseases are likely to dampen the long-term growth outlook for this class of biologics.
Fusion proteins
Fusion proteins represent the fourth largest selling category of biologics (Fig. 3) . After more than five years of high double-digit growth, this category showed a dramatic slowdown in 2008 to low single-digit rates. Fusion proteins that have been on the market for a while are Amevive (alefacept; extracellular CD2 binding protein fused with the Fc region of IgG1; Astellas Pharma, Tokyo) for psoriasis; Enbrel (recombinant TNF-α receptor fused to IgG fragment) for rheumatoid arthritis; Ontak (denileukin diftitoxrecombinant; IL-2 fused to diphtheria toxin; Ligand Pharmaceuticals, San Diego) for T-cell lymphomas; and Orencia (abatacept; IgG fused with the extracellular domain of CTLA4; BMS) for rheumatoid arthritis. Two recently approved fusion proteins are Regeneron's Arcalyst (also known as IL-1 trap) for CAPS and Amgen's Nplate (romiplostim, a 60-kDa peptide with a thrombopoietin receptor (Mpl)-binding domain) for idiopathic thrombocytopenia purpura.
In 2008, the combined US sales of these six brands were $3.8 billion, a 4% rise over their 2007 sales (Fig. 3) . Almost 90% of these sales, however, belong to Amgen's Enbrel, 2008 US sales of which were $3.37 billion, a 1% decline from its 2007 sales. Although Enbrel continues to be the biggest selling biologic in the United States, it is experiencing a declining trend in its sales. Because Enbrel's wholesale price was increased by 5-6% in 2008 and 7% in the second quarter of 2009, on a per-unit basis, its sales actually declined by mid single-digit rates. Enbrel's current decline in US sales is driven primarily by Humira's share gains in the dermatology market. In the rheumatology market, Enbrel remains a market leader, to replace growth factors as the second highest-selling class of biologics. Sales growth of hormones was mainly driven by high growth in insulin analogs.
Insulin sales grew by 25% in 2008 primarily due to large increases in sales of rapid-acting and long-acting analogs (Fig. 6) . 8, 9 . Although the data are preliminary, FDA issued a cautionary note, which led to a slowdown in sales of Lantus. In the second quarter, growth of Lantus slowed to 2%, compared with 13% in the previous quarter. Currently, Lantus sales constitute 36% of the insulin market sales. The slowdown in Lantus sales observed in the second quarter could be a temporary shift; however, if the trend continues it could lower the sales growth of the insulin market and would negatively affect the overall sales growth of the biologics market. Interestingly, these safety issues do not seem to have a class effect, as the 'new on the block' long-acting insulin, Novo Nordisk's Levemir (insulin detemir), continues to grow at high double-digit rates. In 2008, Levemir's sales grew 92% to reach ~$300 million; in the first disease. In two reports, the US Government Accountability Office and the Medicare Payment Advisory Commission have endorsed expanding the current partially bundled payment system to include separately billable services under a fully bundled prospective payment system 6, 7 . Currently, EPOs are billed separately, leading to an incentive to overutilize these drugs. If bundled, payment by the US Centers for Medicaid Services would be capped (at $235 in 2006 dollars per treatment), which would force renal treatment facilities to manage costs. This could potentially lower usage of EPO products in favor of less costly treatments for anemia, like iron supplements.
Sales of the other major market segment in growth factors, granulocyte colony-stimulating factor (G-CSF), used for treating neutropenia, have remained stable, though partly driven by price increases. In 2008, sales of Neulasta (pegfilgrastim) and Neupogen (filgrastrim) both Amgen drugs, were ~$3.1 billion and $1 billion, respectively, a small decline based on unit sales. A majority of G-CSF use is for treatment of chemotherapy-induced neutropenia or febrile neutropenia. Because the newer generation of FDA-approved chemotherapies and several others that are currently in clinical trials cause a relatively lower incidence of neutropenia, in the long term, this market is unlikely to experience growth.
Hormones
Hormones represented the most rapidly growing category of biologics in 2008, with their total US sales reaching $8.5 billion at an overall growth rate of 18% YoY (Fig. 3) . At this growth rate, in less than two years, hormones are likely sclerosis market has saturated, to gain more revenues, all three manufacturers have been continuously raising the price of their drugs by double digits. Since 2001, Biogen Idec's (Cambridge, MA, USA) Avonex (recombinant IFN-β1a produced in Chinese hamster ovary (CHO) cells) has been the highest selling molecule in this category. But during the past four years, it has been losing ground to Merck Serono's (Geneva) Rebif (recombinant IFN-β1a produced in CHO cells) and Berlex Lab's (now Bayer HealthCare) Betaseron (recombinant IFN-β1b produced in Escherichia coli). In 2008, sales of Rebif and Betaseron grew by 18% and 27%, respectively, whereas Avonex sales grew by only 6% (despite an ~20% price increase). In the first quarter, the prices of these three brands were again raised by 6-10%. In the future, a major threat to this class is from novel small molecules that are currently in late stages of development, especially Novartis's oral drug FTY720 (fingolimod, sphingosine (Figs. 3 and 7a) . Cytokines can be classified into four major types of molecules-interferon (IFN)-α, IFN-β, IFN-γ and the interleukins. The sales of IFN-β increased but there was a decline in sales of IFN-α, IFN-γ and interleukins.
IFN-β brands, indicated for multiple sclerosis, are the biggest sellers in the cytokines markets. In 2008, sales of IFN-β increased by 14%, driven by 20-23% price increases for all three marketed brands. As the multiple with a share of 34-35%. Even so, the long-term outlook for Enbrel does not look rosy; with two new anti-TNF-α molecules on the block, Cimzia and Simponi, this market is getting crowded, which could lead to a further decline in Enbrel's US sales.
One biologic in this category showing rapid growth rates is BMS's Orencia, indicated for treatment of individuals with rheumatoid arthritis who have had an inadequate response to other drugs, primarily anti-TNF-α mAbs. Because Orencia inhibits inflammation by blocking CTLA4 signaling, it offers an additional mechanism of action for treating arthritis. Orencia's US sales have grown fourfold, from $91 million in 2006 to $360 million in 2008. According to the company's update in the second quarter, the number of total patients on Orencia grew by 54%, several times the growth rate of the rheumatoid arthritis market. As the uses of anti-TNF-α molecules expand into other indications, a larger pool of patients is created who would be eligible to receive Orencia. BMS is developing a subcutaneous formulation of Orencia and is further testing this drug in psoriatic arthritis and lupus nephritis patients.
Amgen's Nplate is also showing moderate potential for growth. It was approved by the FDA in August 2008 for long-term treatment of adult chronic immune thrombocytopenic purpura. Though Nplate has been on the market for less than year, in the second quarter its US sales were $28 million, which extrapolates to annual sales of more than $100 million. Amgen is currently testing Nplate in chemotherapyinduced thrombocytopenia, which has a large market potential. Interestingly, this will be the third type of biologic (after EPO and G-CSF) that would be used by medical oncologists for supportive treatment of cancer patients. In the future, if the Enbrel slowdown continues, Nplate and Orencia could add a few digits of growth to the fusion proteins market.
Regeneron's Arcalyst is a niche player, as CAPS affect only few hundred people in the plans, leading them to decrease their office stocking of Gardasil. To address these reimbursement concerns, Merck has launched a 'dose replacement program' , providing physicians with a limited number of free replacement doses when they administer the vaccine to privately insured 19-to 26-year-old women, whose insurance plans might not cover HPV vaccination. Despite these efforts, in 2009, Gardasil sales have continued to decline; Gardasil sales in the second quarter were ~$110 million, a 28% decrease over the same quarter in 2008. Early this year, the FDA denied for the second time regulatory approval for use of Gardasil in women between the ages of 27-45 (where preexisting infection with HPV is more likely than in younger women, making the vaccine less effective). Gardasil recently won FDA approval for males.
Ceravix recently was approved by the FDA; this launch could steal some market share from Gardasil. In September, FDA's Vaccines and Related Biological Products Advisory Committee made favorable recommendations for both Cervarix and Gardasil.
Blood factors
Blood factors represent one of the smaller high-growth markets in the biologics sector; the seven brands that comprise this category generated US sales of ~$1 billion in 2008. Their sales grew by 10% in 2008 (Figs.  3 and 8a) . Three blood factors make up this market: factor VIII, factor VIIa and factor IX. More than half of the sales in this category belong to Novo Nordisk's NovoSeven (eptacog alfa; recombinant activated factor VII). In 2008, NovoSeven's sales grew by 8% owing to the launch of its next-generation version of NovoSeven, NovoSeven RT (eptacog alfa formulated with sucrose and l-methionine), which is stable at room temperature. Because of NovoSeven's market leader status, within its first year of launch, NovoSeven RT reported ~$200 million of sales. The combined sales of factor VIII and factor IX brands were ~$470 million in 2008 in the United States, a 12% increase over their 2007 sales. This increase was driven by ~20% growth in sales of Wyeth's Benefix (recombinant factor IX).
Anticoagulants
The thrombolytics/anticoagulants segment is one of the smaller biologics markets and has been experiencing consistently declining sales. The past five years have seen combined US sales for molecules in this category contract from $347 million in 2004 to $332 million in 2008 (Figs. 3 and 8b) . These molecules clear blood clots through an enzymatic mechanism that dissolves fibrin. There are three types of syndrome, several other manufacturers have entered this market and have launched enzyme and non-enzyme therapies for rare genetic disorders. Other enzyme players include Shire (Basingstoke, UK), which markets Elaprase; Biomarin (Novato, CA, USA), which markets Naglazyme; and Genentech, which markets Activase (alteplase). Many of these enzyme replacement therapies for orphan disorders are coming under increasing pressure from other companies that are embracing the niche model; thus, Regeneron and Novartis have recently entered the market for CAPS (Arcalyst and Ilaris, respectively), and recently, GSK announced that they are planning to develop therapies for rare genetic disorders.
In 2009, Genzyme suffered major setbacks when in March, the FDA issued a warning letter regarding its manufacturing facility in Boston and later in June, Genzyme reported that its manufacturing plant was contaminated with a virus, Vesivirus 2117. These events put on hold the shipment of products Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta) and have further delayed the FDA approval of its expanded supply manufacturing application for Myozyme (newly branded as Lumizyme). Because of the shortage in the supply of these drugs, FDA approached Shire and Protalix Biotherapeutics (Carmiel, Israel) to consider submitting a treatment protocol for using their biologic enzyme replacement candidates in patients with Gaucher disease. These events have not only slowed the near-term growth of Genzyme's product, but also provided Shire and Protalix with an easy entry point into the Gaucher disease market.
Recombinant vaccines
During 2008, the US sales of recombinant vaccines fell from $1.4 billion to $1 billion (Figs. 3 and 7c) , a 26% decrease YoY. Though a dramatic fall, this trend is typically observed with sales of vaccines; they peak one or two years after launch and then fall and stabilize at a lower level. More than 70% of US sales of vaccines are attributed to Merck's (Whitehouse Station, NJ, USA) human papilloma virus (HPV) vaccine Gardasil, indicated for prevention of HPV (types 6, 11, 16 and 18) in girls and women between the ages of 9 and 26 years. The decline in sales is due to a combination of factors. First, there is already a high percentage of 11-18 years olds who have had their first dose of Gardasil. Second, Merck is facing challenges in vaccinating the 19-26 year olds due to relatively lower efficacy in that population as compared with 11-18 year olds. Third, several physicians have reported difficulty in obtaining adequate reimbursement from managed care 1-phosphate receptor modulator). In a headto-head trial called TRANSFORMS, FTY720 demonstrated much higher efficacy than IFN-β-a 38-52% reduction in relapse rate. If fingolimod ultimately receives approval, it could therefore cause further decline in sales of the IFN-β category 10 .
IFN-α brands, indicated for hepatitis C, generated US sales of $830 million in 2008, a 3% decline from their 2007 sales, mainly due to saturation of this market. Roche's Pegasys, an IFN-α produced in E. coli, maintained its market leader status in 2008. In the future, this market could experience a rebound, as several novel small-molecule candidates in late stages of development point toward their combination use with IFN-α, potentially for a longer duration of treatment.
A last group of cytokines had combined 2007 US sales of $125 million and includes: Actimmune (an IFN-γ; Intermune, Brisbane, CA, USA), indicated for chronic granulomatous disease; Kineret (anakinra, a recombinant nonglycosylated form of IL-1 receptor antagonist; Amgen), indicated for rheumatoid arthritis; Neumega (recombinant IL-11 receptor agonist in E. coli; Wyeth, Madison, NJ, USA, formerly Genetics Institute), indicated for chemotherapy-induced thrombocytopenia; and Proleukin (aldesleukin; recombinant IL-2; Chiron, Emeryville, CA, USA, now part of Novartis), indicated for melanoma. Their sales fell by 16% during 2007, likely due to rapid saturation of their niche indications and competition from other biologics marketed for similar indications.
Therapeutic enzymes
Therapeutic enzymes represent one of the smaller high-growth markets in the biotech sector. In 2008, eight different brands of enzymes generated US sales of ~$1.07-1.17 billion, a 15-20% increase over their 2007 sales (Figs. 3 and 7b) . The high growth in this market has been mainly driven by double-digit growth in sales of newer products (Naglazyme (galsulfase) for Maroteaux-Lamy syndrome/ mucopolysaccharidosis VI; Myozyme (alglucosidase alfa, Genzyme) for Pompe disease and Elaprase (idursulfase) for Hunter syndrome/ mucopolysaccharidosis II). For most of these products, their manufacturers do not break out the US sales, so I have provided an estimate assuming 20-30% of worldwide sales were generated in the United States.
The business model for this market was pioneered by Genzyme (Cambridge, MA, USA): therapies priced at $200,000-$500,000 per patient per year for ultra orphan disorders. Because of Genzyme's success with such molecules as Ceredase (alglucerase) in Gaucher's factors and therapeutic enzymes-that grew by double-digit rates in 2008. Whereas these classes of biologics grew in 2008, all showed a slowdown compared with their growth rate in 2007. For example, from 2007 to 2008, the mAb growth rate declined by ~50% (from 22% to 12%) and the hormone growth rate declined from 30% to 20%. MAbs for cancer, with the exception of Avastin, are also showing signs of saturation. Similarly, the anti-TNF-α market is exhibiting signs of falling growth rates. Although these analyses point to near-term slowdown in sales growth, several new promising biologic candidates are in the pipeline. Successful launches could bring back some growth in the US biotech sector.
ing with products, it is likely that it could lead to pricing pressure, eventually leading to a decrease in sales. The best example is the human growth hormone market, which has seven marketed brands; the last two growth hormones launched in this area, Tev-Tropin (Teva, Petach Tikva, Israel) and Omnitrope (biosimilar human growth hormone, Sandoz, Basel), launched with a wholesale price discount of 35-45% (ref. 11). Similar crowding is now apparent in the anti-TNF-α market, which currently has five marketed brands. The price wars are likely to exacerbate when biogenerics officially launch in the United States. As there are already at least eight manufacturers-Hospira (Lake Forest, IL, USA), Stada (Bad Vilbel, Germany), Biopartners (Baar, Switzerland), Hexal Biotech (Holzkirchen, Germany), Merck BioVentures, Teva, Biocon (Bangalore, India), Dr. Reddy's (Hyderabad, India)-eyeing the follow-on biologics market, pricing could become a competing factor.
Another potential pricing hurdle for biologics is the change in payment structure by the US Centers for Medicaid Services, the US body that manages finances for Medicare and Medicaid programs. An example is the imminent bundling of payment for use of erythropoietin to manage anemia in chronic kidney disease. Historically, whenever providers have been forced to manage budgets, a decline in product utilization followed together with increasing price wars between competitors. One example that illustrates this is the sales of EPO in Germany, which experienced a steep decline in price because physicians are forced to manage their budgets, creating incentive to purchase the least expensive product in the market. In the future, as US payers come under cost pressure and more markets get crowded, the pricing and reimbursement environment could become a major factor affecting the sales of biologics.
Among growth drivers, there are four categories of biologics-mAbs, hormones, blood anticoagulants: tissue plasminogen activator or tPA; recombinant hirudin, which is an inhibitor of thrombin; and activated protein C, which has antithrombic activity.
Among anticoagulants, four brands experienced a decline of 11-19% during 2008: TNKase (tenecteplase Genentech), Retavase (reteplase; EKR Therapeutics, Bedminster, NJ, USA), Refludan (lepirudin; Bayer HealthCare) and Xigris (drotrecogin alfa (activated); Eli Lilly). Xigris, a protein C therapy indicated for severe sepsis, continues to struggle owing to the absence of clear clinical guidelines and reimbursement from private payers. The only anticoagulant to experience an increase in sales in 2008 was Genentech's tPA Activase, whose sales reached $158 million, a rise of 18%. Activase's special formulation called Cathflo Activase, used to clear blood clots in catheters, rose in sales owing to share gain from other anticoagulants.
Conclusions
The US biotech sector grew at single-digit rates during 2008, marking a slowdown compared with past annual double-digit growth rates. A combination of safety issues and market saturation has led to this. The largest drop in 2008, growth factor sales, was due to label and reimbursement changes for the EPO brands, which lowered their sales volume by 11%. In addition, this year, three new safety issues appeared: first, PML deaths in patients receiving Raptiva, Rituxan (as well as more cases with Tysabri); second, thyroid cancer with GLP-1 analogs; and third, risk of cancer with long-acting Lantus 8, 9 . These concerns have led to a slowdown in sales of all these types of biologics. Because most biologics have higher risk/benefit ratios (severity of diseases, sicker patient population and complex mechanism of actions) than traditional small molecules, the risk of adverse events over time is likely to continue to slow down sales.
The second factor affecting biologics sales is market saturation. Among the nine classes of biologics, four categories of biologics grew in sales, whereas five experienced a decline. Except for EPOs, the other three classes-cytokines (mainly IFN-β brands), recombinant vaccines (75% of sales belonging to Gardasil) and anticoagulants-all experienced falling sales on a per-unit basis because of market saturation. Fusion proteins, of which 90% of the sales belong to Enbrel, saw a decline in unit sales due to saturation of the rheumatology market and loss of share in the dermatology market. In some of these saturated markets, manufacturers are generating additional sales by raising their prices by 10-20%.
Although price increases have become common, as more markets show signs of crowd- 
